Recent Company News

• 09:58 PM ET Jun 25, 2025
  

  StreetAccount Summary - Australia unusual volume traders

• 06:39 PM ET Jun 22, 2025
  

  Immutep initial data from Phase I study of IMP761 shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg (A$0.24, 0.00)

• 09:44 PM ET May 05, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 06:32 PM ET May 25, 2025
  

  Immutep's Phase II trial evaluating efti with radiotherapy plus KEYTRUDA in neoadjuvant setting for resectable STS has met primary endpoint (A$0.30, 0.00)

• 06:26 PM ET May 14, 2025
  

  Immutep reports 60.8% response rate and 90.2% disease control rate achieved in investigator-initiated INSIGHT-003 trial as of data-cut off date 6-May (A$0.28, 0.00)

• 07:24 PM ET May 05, 2025
  

  Street Takeaways - Immutep efti + Keytruda result update (A$0.31, 0.00)

• 04:32 PM ET May 05, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market